Walleye Trading
KALV

Walleye Trading’s KalVista Pharmaceuticals KALV Stock Holding History

Walleye Trading’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,000
Closed -$123K – 5057
2023
Q4 		$123K Buy
+10,000
New +$91K ﹤0.01% 4053
2021
Q4 		– Sell
-6,400
Closed -$112K – 5601
2021
Q3 		$112K Buy
+6,400
New +$130K ﹤0.01% 4300

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Walleye Trading's KALV Position: Q4 2022 in Review

Walleye Trading sold out of KalVista Pharmaceuticals (KALV) in Q4 2022, closing a stake of 16,301 shares — an estimated $237K sold.

Walleye Trading first reported a position in KALV in Q3 2022 and held it in 1 quarter. The position peaked at $237K in Q3 2022. 91 funds tracked by Wall St. Rank hold KALV as of Q4 2022.

  • Walleye Trading reported no remaining KalVista Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Walleye Trading sold 16,301 KalVista Pharmaceuticals shares in Q4 2022, an estimated $237K.
  • Walleye Trading first reported a position in KalVista Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Walleye Trading's KalVista Pharmaceuticals position peaked at $237K in Q3 2022.
  • 91 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2022.

Based on Walleye Trading's 13F filing for Q4 2022, filed 14 Feb 2023.